{
    "nctId": "NCT05754528",
    "briefTitle": "Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance",
    "officialTitle": "A Pragmatic Randomised, Trial Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance (REaCT-TEMPO)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 240,
    "primaryOutcomeMeasure": "1-year adherence with prescribed endocrine therapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with an early stage or locally advanced hormonal receptor positive breast cancer\n* Plan to receive endocrine therapy\n* Able to provide oral consent\n* Willing and able to complete questionnaires as per study protocol\n\nExclusion Criteria:\n\n* Metastatic cancer\n* Adjuvant abemaciclib",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}